Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Filing 118

ORDER by Judge Haywood S. Gilliam, Jr. Granting 117 Stipulation to Permit Depositions After the Fact Discovery Cutoff Date. (ndrS, COURT STAFF) (Filed on 1/14/2019)

Download PDF
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 DURIE TANGRI LLP DARALYN J. DURIE (SBN 169825) ddurie@durietangri.com LAURA E. MILLER (SBN 271713) lmiller@durietangri.com RAGHAV R. KRISHNAPRIYAN (SBN 273411) rkrishnapriyan@durietangri.com MATTHEW W. SAMUELS (SBN 294668) msamuels@durietangri.com 217 Leidesdorff Street San Francisco, CA 94111 Telephone: 415-362-6666 Facsimile: 415-236-6300 YOUNG BASILE HANLON & MACFARLANE, P.C. JEFFREY D. WILSON (Pro Hac Vice) wilson@youngbasile.com ANDREW R. BASILE, JR. (SBN 208396) abasile@youngbasile.com EDDIE D. WOODWORTH (Pro Hac Vice) woodworth@youngbasile.com RYAN T. MCCLEARY (Pro Hac Vice) mccleary@youngbasile.com 3001 W. Big Beaver Road, Suite 624 Troy, MI 48084 Telephone: (248) 649-3333 Facsimile: (248) 649-3338 MCDERMOTT WILL & EMERY LLP Thomas P. Steindler (Pro Hac Vice) tsteindler@mwe.com 500 N. Capitol St, NW Washington, DC 20001 Telephone: 202-756-8000 MCDERMOTT WILL & EMERY LLP William G. Gaede, III (SBN 136184) wgaede@mwe.com 275 Middlefield Road, Suite 100 Menlo Park, CA 94025 Telephone: 650-815-7400 Facsimile: 650-815-7401 MCDERMOTT WILL & EMERY LLP K. Nicole Clouse (Pro Hac Vice) nclouse@mwe.com 28 State Street Boston, MA 02109 Telephone: 617-535-3841 Attorneys for Defendant NOVARTIS PHARMACEUTICALS CORPORATION Attorneys for Plaintiff PLEXXIKON INC. 17 IN THE UNITED STATES DISTRICT COURT 18 FOR THE NORTHERN DISTRICT OF CALIFORNIA 19 OAKLAND DIVISION 20 PLEXXIKON INC., 21 22 23 24 25 Case No. 4:17-cv-04405-HSG Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION, STIPULATION AND ORDER TO PERMIT DEPOSITIONS AFTER THE FACT DISCOVERY CUTOFF DATE Ctrm: 2 – 4th Floor Judge: Honorable Haywood S. Gilliam, Jr. Defendant. 26 27 28 STIPULATION AND ORDER TO PERMIT DEPOSITIONS AFTER THE FACT DISCOVERY CUTOFF DATE / CASE NO. 4:17-CV-04405-HSG 1 Pursuant to Northern District of California Civil Local Rules 6-2 and 7-12, Plaintiff Plexxikon 2 Inc. (“Plexxikon”) and Defendant Novartis Pharmaceuticals Corporation (“NPC”) stipulate and request 3 that the Court enter an order permitting the parties to take certain depositions after the January 17, 2019 4 close of fact discovery. Specifically, Plexxikon requests to take the depositions of third-party witnesses 5 John Stellwagen, Christina Schwarz, and Zuosheng Liu, and NPC requests to take the depositions of 6 Plexxikon and third-party witnesses Chao Zhang, Wayne Spevak, and Kathleen Glaub, on or before 7 February 6, 2019. Plexxikon further requests to take the continued 30(b)(6) deposition of non-party 8 witness GlaxoSmithKline (“GSK”) on or before February 6, 2019, and be permitted to rely on documents 9 produced by GSK after the close of fact discovery. 10 On December 22, 2017, the Court issued a scheduling order setting deadlines through claim 11 construction. See ECF No. 57. On June 5, 2018, the parties filed a joint motion to amend the scheduling 12 order and set a schedule for the remainder of the case. See ECF No. 76. The Court issued a revised 13 scheduling order on June 20, 2018, setting, in relevant part, a fact discovery cutoff date of January 17, 14 2019, an opening expert report exchange date of February 4, 2019, an expert discovery cutoff date of 15 May 2, 2019, and a trial date of October 7, 2019. See ECF No. 80. This order explained that “[t]hese 16 dates may only be altered by order of the Court and only upon a showing of good cause.” Id. at 1. There 17 have been no subsequent time modifications in this case, either by stipulation or Court order. 18 Permitting the parties to take these depositions on the aforementioned dates will not affect any of 19 the remaining dates set by the Court’s June 20, 2018 Revised Scheduling Order. Moreover, good cause 20 exists to take these depositions after the close of fact discovery. The parties have been working 21 diligently to schedule depositions, but witness and attorney schedules, including the need to coordinate 22 with counsel for third-party witnesses, have made it necessary to schedule these few depositions after the 23 January 17, 2019 fact discovery cutoff date. The parties agree that they will not use the depositions of 24 the non-GSK witnesses as a basis for seeking a stay. 25     26 27 28 1 STIPULATION AND ORDER TO PERMIT DEPOSITIONS AFTER THE FACT DISCOVERY CUTOFF DATE / CASE NO. 4:17-CV-04405-HSG 1 Dated: January 14, 2019 2 DURIE TANGRI LLP By: 3 4 Attorney for Plaintiff PLEXXIKON INC. 5 6 /s/ Matthew W. Samuels MATTHEW W. SAMUELS Dated: January 14, 2019 7 McDERMOTT WILL & EMERY LLP By: /s/ Thomas P. Steindler THOMAS P. STEINDLER 8 Attorney for Defendant NOVARTIS PHARMACEUTICALS CORPORATION 9 10 11 FILER’S ATTESTATION 12 13 14 15 Pursuant to Civil L.R. 5-1(i)(3), regarding signatures, I, Matthew W. Samuels, attest that concurrence in the filing of this document has been obtained. Dated: /s/ Matthew W. Samuels MATTHEW W. SAMUELS 16 17 18 19 20 21 22 23 24 25 26 27 28 2 STIPULATION AND ORDER TO PERMIT DEPOSITIONS AFTER THE FACT DISCOVERY CUTOFF DATE / CASE NO. 4:17-CV-04405-HSG 1 2 ORDER PURSUANT TO STIPULATION, IT IS SO ORDERED. 3 4 Dated: 1/14/2019 HON. HAYWOOD S. GILLIAM, JR. UNITED STATES DISTRICT JUDGE 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 3 STIPULATION AND ORDER TO PERMIT DEPOSITIONS AFTER THE FACT DISCOVERY CUTOFF DATE / CASE NO. 4:17-CV-04405-HSG

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?